MedPath

Auranofin

Generic Name
Auranofin
Brand Names
Ridaura
Drug Type
Small Molecule
Chemical Formula
C20H34AuO9PS
CAS Number
34031-32-8
Unique Ingredient Identifier
3H04W2810V

Overview

Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme oxygenase 1 is an inducible heme-degrading enzyme with anti-inflammatory properties.

Indication

Used in the treatment of active, progressive or destructive forms of inflammatory arthritis, such as adult rheumatoid arthritis.

Associated Conditions

  • Rheumatoid Arthritis

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/02/03
Not Applicable
Not yet recruiting
Federal University of São Paulo
2018/03/07
Phase 2
Terminated
2016/11/21
Phase 2
UNKNOWN
The Aurum Institute NPC
2016/11/11
Not Applicable
Completed
Federal University of São Paulo
2016/05/12
Phase 1
Completed
University of Ulm
2016/04/13
Phase 2
Completed
2014/06/26
Phase 1
Withdrawn
Vaccine and Gene Therapy Institute, Florida
2014/04/30
Phase 1
Withdrawn
2014/03/17
Phase 1
Completed
2014/02/14
Phase 2
Completed

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
Ridaura Tablets
13000
Medicine
A
8/14/1991

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
RIDAURA
xediton pharmaceuticals inc
01916823
Capsule - Oral
3 MG
12/31/1993

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.